Researchmoz added Most up-to-date research on “PharmaSphere: Emerging Biotechnologies – Stem Cell Therapy” to its huge collection of research reports.
“PharmaSphere: Emerging Biotechnologies Stem Cell Therapy”, provides strategic analysis of the global stem cells industry. It discusses key development trends, regulatory requirements in various markets, recent deals activity and industry dynamic trends, as well as describes the operations strategy of these companies. Furthermore, it includes a geographical segmentation of various markets including the EU and US, as well as emerging markets such as China, India, SouthKorea, and Israel-providing in-depth analysis of these markets regulatory framework, key domestic players and their stem cell pipelines, and strategic outlook.
Throughout the report, GlobalDatas analysts provide you with expert insight, expanding on each strategy and factor discussed, with the aim of providing you with the tools needed for making informed business decisions.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=232165
Stem Cell Market Dynamics: This report provides analysis of the key drivers and trends shaping the global Stem Cell therapy market, including manufacturing, emerging markets, and development pipeline.
Financial Performance Insight: Report uses GlobalDatas proprietary data across 22 key financial metrics to provide insight over stem cell company performance.
PipelineAnalysis: Detailed information on ten leading stem cell therapies; trend analysis of clinical trial studies and investigators covering over 1000 trials related to stem cell therapies.
Deal strategies: Exhaustive discussion on the strategic implications and synergies of deals including, M&A, collaboration as well as capital raisings such as equity offerings, private equity and venture financing activities.
Regulatory Implications: Guidelines for stem cell usage for developing therapies in seven major markets for stem cells including US, Europe, Japan, SouthKorea, Israel, China and India.
Company Analysis: Company landscape covering 40 companies on full pipeline, financials and key overview information.
Reasons to buy
Identify the key domestic players in various stem cell markets, including South Korea, Japan and emerging markets such as India and China.
Understand the key drivers and trends in the global stem cell industry.
Analyze and track the strategies that companies are using to enter and/or strengthen their position in the evolving stem cell industry, as well as efforts being made by innovator companies like Pfizer and Novartis to enter this market.
Use this information as an independent source for your due diligence and transaction strategy.
Understand the regulatory framework and be prepared to tackle challenges facing the stem cell based therapies.
Key Questions Answered
What are the key market drivers of the global stem cell industry?
Who are the top players involved in the development of stem cell therapies in developed as well as developing countries?
What are the main regulatory measures affecting the stem cell industry in the US, Europe, Japan, India, South Korea, China and Israel?
What are the major trends in stem cell clinical trials and profiles of key investigators?
What specific strategies are companies utilizing to combat some of the challenges currently facing the development of therapies in the global stem cell industry?
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=232165
Table Of Content
1 Table of Contents 6
1.1 List of Tables 14
1.2 List of Figures 19
2 Introduction 22
2.1 Report Scope 22
2.2 Upcoming Related Reports 24
2.3 Recently Published Reports 24
3 Stem Cell Overview 25
3.1 Definition 25
3.1.1 Renewal 25
3.1.2 Potency 25
3.2 Types of Stem Cell 26
3.2.1 Embryonic Stem Cells 27
3.2.2 Adult Stem Cells 27
3.2.3 Induced Pluripotent Stem Cells 28
3.2.4 Cord-Blood-Derived Stem Cells 28
3.2.5 Amniotic Stem Cells 28
3.2.6 Fetal Stem Cells 28
3.3 Stem Cell Research Timeline 29
3.4 Therapeutic Applications 30
3.4.1 Cardiovascular 30
3.4.2 Central Nervous System 30
3.4.3 Diabetes 30
3.4.4 Oncology 31
3.4.5 Ophthalmology 31
3.4.6 Musculoskeletal Disorders 32
3.5 Intellectual Property 32
3.5.1 United States 32
3.5.2 Europe 33
3.5.3 Japan 34
4 Stem Cell Pipeline 35
4.1 Development Stages 37
4.2 Therapy Areas 39
4.3 Indications 40
4.4 Platform Technology Transfers 42
4.4.1 Types of Stem Cell Platform Technologies 42
4.4.2 Partnerships Between Universities and Companies 43
4.5 Stem Cell Pipeline in Focus 44
4.5.1 Prochymal (Mesoblast) 44
4.5.2 Adult Autologous CD34+ Stem Cells (Baxter) 45
4.5.3 StemEx (Gamida Cell) 46
4.5.4 Allogeneic MPC for Bone Marrow Transplantation (Mesoblast) 47
4.5.5 Preob (Bone Therapeutics) 48
4.5.6 Cerecellgram (Pharmicell) 49
4.5.7 Revascor or CEP-41750 (Mesoblast) 50
4.5.8 Tumor Stem Cell Specific Dendritic Cell Therapy (Neostem Oncology) 51
4.5.9 GSK-2696273 (GlaxoSmithKline) 52
4.5.10 Lenti-D (Bluebird bio) 53